Cemiplimab monotherapy offers a significant overall survival benefit compared with platinum-doublet chemotherapy for advanced non-small-cell lung cancer patients with a PD-L1 tumor cell expression of 50% or above, indicate initial EMPOWER-Lung 1 trial findings.

CheckMate 9LA trial findings indicate that a front-line nivolumab plus ipilimumab-based regimen slows the decline in health-related quality of life for advanced non-small-cell lung cancer patients compared with chemotherapy alone.

CHRYSALIS trial findings suggest that the bispecific monoclonal antibody amivantamab could be combined with the third-generation EGFR–tyrosine kinase inhibitor lazertinib for the treatment of patients with metastatic or unresectable non-small-cell lung cancer with an EGFR exon 19 deletion or L858R mutation.

Two phase 2 studies presented at the ESMO Virtual Congress 2020 have highlighted the risks and benefits of neoadjuvant immunotherapy in patients with resectable non-small-cell lung cancer.

Treatment with pembrolizumab has led to a near doubling of the 5-year overall survival rate relative to chemotherapy among previously untreated patients with PD-L1-high, metastatic non-small-cell lung cancer, report the KEYNOTE-024 investigators.

First-line treatment with lorlatinib significantly improves progression-free survival, relative to crizotinib, in patients with advanced ALK- positive, non-small-cell lung cancer, results of the phase 3 CROWN study show.

Chemotherapy-naïve patients with nonsquamous non-small-cell lung cancer and EGFR -activating mutations derive prolonged progression-free survival from the addition of apatinib to gefitinib, phase 3 ACTIVE data show.

A progression-free survival of at least 12 months is a strong indicator of good survival outcomes at 2 years in patients with extensive-stage small-cell lung cancer taking durvalumab alongside first-line platinum–etoposide, even in those with poor prognostic factors, analysis of CASPIAN data shows.

Patients with completely resected stage IIIA N2 non-small-cell lung cancer do not benefit from postoperative radiotherapy, show the results of the phase 3 Lung ART trial presented at the ESMO Virtual Congress 2020.

Adjuvant treatment with osimertinib substantially reduces the risk for central nervous system recurrence among patients with resected stage IB–IIIA EGFR -mutated non-small-cell lung cancer, shows an analysis of phase 3 study data.

ETOP/IFCT 4-12 STIMULI findings do not support the use of consolidation nivolumab plus ipilimumab for limited-stage small-cell lung cancer patients who have completed chemoradiotherapy and prophylactic cranial irradiation.

These results were simultaneously published in the Journal of Clinical Oncology . medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2020 Springer Healthcare Ltd, part of the Springer Nature Group ESMO Virtual Congress 2020: 19–21 September J Clin Oncol 2020; doi:10.1200/JCO.20.02514

Julie Brahmer reports on the 5-year overall survival results from the KEYNOTE-024 study of first-line pembrolizumab versus chemotherapy in advanced, PD-L1-positive non-small-cell lung cancer and highlights the key unanswered questions.

Benjamin Solomon highlights the key messages of the CROWN study of lorlatinib in advanced, ALK-positive non-small-cell lung cancer and makes the case for using the agent upfront in these patients.

Masahiro Tsuboi discusses the clinical implications of the primary and CNS analyses of the ADAURA trial of adjuvant osimertinib in EGFR-mutated non-small-cell lung cancer and outlines the key next steps.